References
- Belavy D, Sunn N, Lau Q, Robertson T. 2013. Absence of neurotoxicity with perineural injection of ultrasound gels: assessment using an animal model. BMC Anesthesiol. 13:18. doi:10.1186/1471-2253-13-18
- Bright RJ, Wilkinson J, Coventry BJ. 2014. Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. BMC Neurol. 14:26. doi:10.1186/1471-2377-14-26
- Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, Laine GA, Cox CS Jr. 2009. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 18:683–692. doi: 10.1089/scd.2008.0253
- Gao, J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. 2001. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 169:12–20. doi: 10.1159/000047856
- Hayek SM, Deer TR, Pope JE, Panchal SJ, Patel VB. 2011. Intrathecal therapy for cancer and non-cancer pain. Pain Physician. 14:219–248.
- Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. 2007. Immunotherapy for Guillain–Barré syndrome: a systematic review. Brain. 130:2245–2257. doi: 10.1093/brain/awm004
- Larsen JM, Martin DR, Byrne ME. 2014. Recent advances in delivery through the blood–brain barrier. Curr Top Med Chem. 14:1148–1160. doi: 10.2174/1568026614666140329230311
- Li N, Sarojini H, An J, Wang E. 2010. Prosaposin in the secretome of marrow stroma-derived neural progenitor cells protects neural cells from apoptotic death. J Neurochem. 112:1527–1538. doi: 10.1111/j.1471-4159.2009.06565.x
- Mahdi-Rogers M, Kazmi M, Ferner R, Hughes RA, Renaud S, Steck AJ, Fuhr P, Halter J, Gratwohl A, Tyndall A. 2009. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst. 14:118–124. doi: 10.1111/j.1529-8027.2009.00221.x
- Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. 2009. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 20:419–427. doi: 10.1016/j.cytogfr.2009.10.002
- Murphy MB, Moncivais K, Caplan AI. 2013. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 45:e54. doi:10.1038/emm.2013.94
- Newsom-Davis J. 1988. Autoimmunity in neuromuscular disease. Ann N Y Acad Sci. 540:25–38. doi: 10.1111/j.1749-6632.1988.tb27048.x
- Press R, Askmark H, Svenningsson A, Andersen O, Axelson HW, Strömberg U, Wahlin A, Isaksson C, Johansson JE, Hägglund H. 2014. Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP. J Neurol Neurosurg Psychiatry. 85:618–624. doi: 10.1136/jnnp-2013-306014
- Pulavendran S, Vignesh J, Rose C. 2010. Differential anti-inflammatory and anti-fibrotic activity of transplanted mesenchymal vs. hematopoietic stem cells in carbon tetrachloride-induced liver injury in mice. Int Immunopharmacol. 10:513–519. doi: 10.1016/j.intimp.2010.01.014
- Wadhwa A, Kandadai SK, Tongpresert S, Obal D, Gebhard RE. 2011. Ultrasound guidance for deep peripheral nerve blocks: a brief review. Anesthesiol Res Pract. 2011:262070. doi:10.1155/2011/262070
- Yu J, Zheng C, Ren X, Li J, Liu M, Zhang L, Liang L, Du W, Han ZC. 2010. Intravenous administration of bone marrow mesenchymal stem cells benefits experimental autoimmune myasthenia gravis mice through an immunomodulatory action. Scand J Immunol. 72:242–249. doi: 10.1111/j.1365-3083.2010.02445.x